Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV : Data from the COMBINE ‐2 study

HIV Medicine 2026 Open access

Read full text
Authors: Cristina Mussini, Cassidy Henegar, Lambert Assoumou, S. De Wit, Margaret Johnson, Eugenia Quiros Roldan, Chris Kenyon, C Deschanvres, D. Zucman, Frank A. Post, Roya Movahedi, Laura Comi
+13 more Jo Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh J. Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari
DOI: 10.1111/hiv.70187
Cited by: 1
References: 26

Abstract

OBJECTIVES: This study assessed real-world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe. METHODS: This observational cohort enrolled adults with HIV from 28 sites across Europe who were switching to a two-drug regimen of an INSTI plus a nucleoside reverse transcriptase inhibitor or non-nucleoside reverse transcriptase inhibitor while suppressed [viral load (VL)

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions HIV-related health complications and treatments

Publication details

Journal / source
HIV Medicine
Publisher
Wiley
Volume
27
Issue
4
Pages
572–584
Publication date
7 January 2026
Language
EN